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Absorption via the GI tract or through tissue
Reaches the lymphatic channels and the blood stream
Circulates in the blood until it reaches cholinergic synapses
Binds with the help of binding domain
Cholinergic neuronal cell membrane at nerve terminal
Enters neuron by endocytosis
light chain of the toxin
Crosses the membrane of the endocytic vesicle
Enters cytoplasm of the pre synaptic terminal
cleaves to sites on SNARE proteins
Prevents assembly of synaptic fusion complex
Blocks docking, fusion and acetylcholine release1. Introduction
Botulinum neurotoxin (BTX) is a neurotoxic protein produced
by the Gram-positive, rod-shaped, spore-forming, and strictly
anaerobic bacterium Clostridium botulinum and, rarely, by
Clostridium butyricum and Clostridium baratii, commonly
found on plants and in soil, water, and animal intestinal tracts.
Although once considered lethal, BTX is now used as a thera-
peutic drug. BTX exhibits transient, nondestructive, dose-
dependent, and localized actions, with minimal systemic side
effects (Marchese et al., 2008), underlying its wide use in vari-
ous orofacial and dental disorders. The exact mechanism of
action, dosage, and delivery procedure of BTX are very impor-
tant. In addition to conditions for which BTX is currently used
as a therapeutic agent, evidence supports the expansion of its
indications in dentistry. The purpose of this review is to pro-
vide insights into the current indications of BTX, highlight
its expanding use, and review recent advances in the use of
BTX in dentistry.
2. Sites and modes of action of BTX
Modes of action of BTX are summarized in Table 1
(Muthane and Panikar, 2003). BTX induces muscle weak-
ness by inhibiting transmission of alpha motorneurons at
the neuromuscular junction. Release of acetylcholine (ACh)
is mediated by the assembly of synaptic fusion com-
plexes—a set of soluble N-ethylmaleimide-sensitive factor
attachment protein receptor (SNARE) proteins, including
synaptobrevin, synaptosomal-associated protein (SNAP),
and syntaxin. Seven BTX serotypes have been identiﬁed.
BTX types B, D, F, and G cleave synaptobrevin; types A,
C, and E cleave SNAP-25; and type C cleaves syntaxin
(Kant et al., 2009; Davis, 1993).2.1. Forms of BTX
Commercially available various forms of BTX are summarized
in Table 2 (Rao et al., 2011). Forms of BTX range in weight
Table 2 Forms of botulinum toxin.
Type A – BOTOX
DYSPORT
XEOMIN
Type B – MYOBLOC
NEUROBLOC
Table 4 Current and expanding applications in oro-facial
disorders.
1. Oro-facial pain conditions like trigeminal neuralgia, post-
herpetic neuralgia, migraine, headache and myofacial pain
dysfunction
2. Salivary gland disorders like sialorrhea, sialocele, Frey’s
syndrome etc.
3. Hypertrophy of masseter muscle
4. TMJ disorders like dislocation, bruxism, and oro-
mandibular dystonia and arthritis
5. Trismus
6. Gummy smile
7. Disorders of the facial nerve i.e. Facial nerve palsy/paresis
8. Cancer therapy
9. Botulinum toxin as a carrier for oral vaccines
10. Preparation of oral cavity for microsurgical
reconstruction
11. During dental implant, jaw and periodontal surgeries.
12. In wound healing
13. Treatment of hypertrophic scars
Expanding uses in Dentistry 65from 300 to 900 kD, with the pure toxin, including both light
and heavy chains, typically weighing about 150 kD (Muthane
and Panikar, 2003). Crude toxin is puriﬁed and diluted with
human serum albumin. Each vial of 100 units (U) is reconsti-
tuted with preservative-free normal saline (1–5 ml) immedi-
ately before use. BTX begins to act within 24–48 h of
administration, peaking at 2–3 weeks and maintaining its efﬁ-
cacy for about 3–4 months (Muthane and Panikar, 2003). Sec-
ondary nonresponsiveness could be encountered due to the
production of neutralizing antibodies. To overcome this effect,
newer toxins with higher activity levels are being engineered.
Antibody production could be prevented by avoiding repeated
injections and keeping the dose as low as possible (Nigam and
Nigam, 2010).
2.2. Injection procedure
The BTX dose should be tailored to the severity of the condi-
tion. Toxin is injected with a 1- to 1.5-inch, 25- to 30-gauge
needle, with electromyography (EMG) monitoring. Subse-
quent injections can be given according to the response after
3 months.
3. Adverse effects
Side effects of BTX use (Table 3) are generally transient, but
could last up to several months after administration.4. Applications in dentistry (Table 4)
4.1. Pain disorders
BTX type A inhibits the calcium-dependent release of sub-
stance P in the embryonic dorsal root ganglia, producing an
analgesic effect through peripheral inhibition of C and A delta
ﬁbers (Purkiss et al., 2000). Peripheral and central analgesicTable 3 Side effects of botulinum toxin use.
Systemic side eﬀects include anxiety, dizziness, drowsiness,
headache, dry mouth and eyes, pharyngitis, dysphagia, facial
pain, ﬂu-like symptoms, inability to focus eyes, drooping eyelid
or eyebrow, double/blurred vision, sensitivity to light indigestion,
nausea, sweating, fever, chills, allergic reaction like rash, itching,
dyspnoea, tightness of chest, edema of face, hoarseness of voice,
respiratory infection, anaphylaxis, urticaria, erythema
multiforme, pruritus, loss of bladder control, loss of strength,
paralysis, seizures etc.
Locally, at the injection site side eﬀects include pain, redness,
tingling, bruising, swelling or tenderness, stiﬀ or weak muscles at
or near the site, bleeding etc.effects of BTX arise from the direct and indirect (retrograde
transport) effects of the toxin on peripheral nociceptive
neurons.
4.1.1. Trigeminal and postherpetic neuralgia
When used to treat intractable and idiopathic neuralgia, BTX
type A acts by inhibiting the exocytosis of ACh and other neu-
rotransmitters. This action could be analgesic if it prevents the
release of neuropeptides from nociceptive nerve endings. BTX
type A inhibits the release of norepinephrine and ATP from
postganglionic sympathetic nerve endings, providing an anal-
gesic effect and reducing central and peripheral sensitization.
The appropriate dose of BTX for treating trigeminal neuralgia
is 20–50 U, injected at the trigger zone or into the masseter
muscle (Zuniga et al., 2008).
Recently, BTX type A has been used as an alternative treat-
ment modality for refractory cases of postherpetic neuralgia
(Emad et al., 2011). When provided intradermally at 15 U,
BTX inhibits the release of formalin-induced glutamate, sub-
stance P, and calcitonin gene-related polypeptide (CGRP),
with direct effects on sensory neurons and indirect effects on
the central nervous system (CNS). Pain decreases to mild
and tolerable levels within the ﬁrst week of administration.
4.1.2. Headache and migraine
Headache may be due to abnormal excitation of the peripheral
nociceptive afferent ﬁbers, leading to central sensitization and
an increase in pericranial muscle hardness and tenderness.
Headache may also be due to enhanced responsiveness of the
trigeminal nucleus caudalis neurons, leading to the generation
of pain signals that decrease pain modulation involving sero-
tonin and norepinephrine. Migraine is a neurovascular pain
syndrome associated with sterile inﬂammation and vasodilata-
tion, which activate the trigeminal afferents on the vessel wall
and cause pain. In cluster headache, the ophthalmic branch of
the trigeminal nerve relays a pain signal, leading to the release
of substance P and CGRP, vasodilatation of the dural blood
vessels, and neurogenic inﬂammation.
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have been proposed. (1) BTX may decrease muscle contractil-
ity by preventing ACh release from the presynaptic terminal.
However, this theory does not explain why pain relief with
BTX often occurs before muscle relaxation (Gobel et al.,
2001). (2) BTX may inhibit the extrafusal muscle ﬁbers and
normalize excessive levels of muscle spindle activity (Rosales
et al., 1996; Gobel et al., 2001). Excessive release of ACh at
the neuromuscular junction leads to abnormally high levels
of end-plate activity, resulting in extrafusal muscle contrac-
tion. BTX inhibits transmission of neurotransmitters at the
gamma motorneurons in the muscle spindle and decreases
muscle activity. (3) BTX may enter the CNS, modulating pain
by inhibiting the release of substance P from the trigeminal
nerve endings and activating the expression of substance P in
the raphe nuclei. The BTX-mediated inhibition of SNAP-25
blocks neurotransmitter exocytosis, leading to a decreased
pain through the colocalization of vasoactive intestinal peptide
and neuropeptide Y with ACh in the parasympathetic neurons.
Further contributing to the analgesic effect is the decompres-
sion of afferent nociceptive neurons, which leads to a decrease
in excitatory metabolite levels secondary to muscle relaxation
(Weigand and Wellhoner, 1977). (4) BTX may reduce
parasympathetic outﬂow, leading to analgesia. For this reason,
BTX use is indicated in cases of chronic headache (Goadsby
and Edvinsson, 1994).
Methods of BTX administration currently used include a
ﬁxed-site approach, following the pain, direct injection into
the tender muscles, and a combination of these methods. Gla-
bellar injections can provide complete relief. Other injection
sites include the suboccipital region, where higher or lower
doses are necessary for the posterior or anterior (e.g., frontal
and temporal) regions, respectively. Doses of BTX used for
headache and migraine range from 10 to 150 U, with clinical
improvement within the ﬁrst 2 weeks of injection, maximum
beneﬁt at about 6 weeks, and efﬁcaciousness for 3 months.
For cluster headache, commons doses are 24–150 U of BTX
type A or the equivalent BTX type B (1200 U) (Winner, 2003).
4.1.3. Myofacial pain dysfunction syndrome (MPDS)
A complex pain syndrome with an unclear etiology, MPDS is
associated with pain and tenderness of the muscles, especially
those involved in mastication, and with trigger points/bands.
Injection of 50 U of BTX type A is a simple and effective
means to reduce the muscle hyperactivity of MPDS, by block-
ing ACh release from the neuromuscular junction (Nixford
et al., 2002). Although this mechanism of BTX has been stud-
ied extensively, the results have been inconclusive owing to the
unclear etiology. For example, EMG studies of MPDS
patients have not consistently shown muscle hyperactivity.
Other studies reported myositis as the underlying cause of pain
in MPDS; however, myositis cannot be treated by BTX as the
toxin does not have anti-inﬂammatory activity. Furthermore,
the presence of trigger points in MPDS has not been con-
ﬁrmed. Overall, insufﬁcient prospective randomized controlled
studies have been performed to prove the effectiveness of BTX
use in MPDS. Until recently, BTX has only been used as a
temporary therapy to alleviate pain and dysfunction in the dis-
order (Fallah and Currimbhoy, 2012; Laskin, 2012).4.2. Disorders of the salivary glands
BTX has been used in the treatment of disorders of the salivary
glands, such as sialorrhea, sialocele, and Frey’s syndrome.
When used in the treatment of hypersalivation (sialorrhea),
BTX acts on the cholinergic nerve endings, causing proteolysis
of SNAP-25, chemical denervation, and loss of neuronal activ-
ity. BTX is injected intraglandularly, mainly to the parotid
gland, at a dose that depends on the condition. Common dose
ranges are 10–100 U of Botox or 20–300 U of Dysport (Fuster
Torres et al., 2007). Sialocele is an accumulation of saliva sur-
rounded by a tissue reaction, which develops as a postopera-
tive complication after parotidectomy. When used for this
condition, BTX type A acts by blocking ACh release from
the secretomotor parasympathetic autonomic nerve. Doses of
50–70 U are given percutaneously in the parotid region
(Chow and Kwok, 2003). Another common complication of
parotidectomy, Frey’s syndrome is characterized by facial
hyperhidrosis in the preauricular region initiated by a gusta-
tory stimulus. The mode of action of BTX type A in Frey’s
syndrome involves inhibition of ACh release at the nerve end-
ings and in the muscles, and blockade of the motor end plates.
At the autonomic level, sweat secretion is blocked in glands
that depend on ACh release for their activation. BTX is typi-
cally administered at 30 U, and its efﬁcacy lasts 6–15 months.
Repeated administration decreases the symptom severity,
reduces the extent of the affected area, and increases the time
to relapse (Diaz et al., 2008).
4.3. Masseter muscle hypertrophy
Injection of BTX type A is a minimally invasive treatment
modality for massetric hypertrophy, deﬁned as the asymp-
tomatic enlargement of one or both masseter muscles. The
masseter muscle is injected with 100 U of BTX type A in
2 ml of sterile saline. The only limitation of this therapy is
recurrence after 6 months, when the procedure must be
repeated (Bas et al., 2010).
4.4. Temporomandibular disorders (TMDs)
TMDs are a group of nonodontogenic facial pain disorders
associated with the temporomandibular joint (TMJ) or associ-
ated muscles.4.4.1. TMJ dislocation
Dislocation of the TMJ is caused by excessive forward move-
ment of the condyle beyond the articular eminence, with com-
plete separation of the articular surfaces and positional
ﬁxation. By inhibiting ACh release at the neuromuscular junc-
tion and weakening the lateral pterygoid muscles via chemod-
enervation, BTX type A causes an imbalance between the
muscles used for opening and closing the jaw. These effects
of BTX limit mouth opening and help to prevent dislocation
(Fu et al., 2010), with effects lasting 2–4 months. The BTX
dose for this purpose is 25–50 U, injected percutaneously into
each lateral pterygoid muscle.
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Observed in individuals while awake or asleep, bruxism is an
involuntary disorder manifested by jaw clenching, tooth
gnashing, and grinding. For bruxism treatment, BTX type A
is injected into the masseter muscle at 60 U per side. A dose
range of 25–100 U elicits a good response for up to 3–4 months
(Tan and Jankovic, 2000).
4.4.3. Oromandibular dystonia
These involuntary spasms of the masticatory, lingual, and pha-
ryngeal muscles result in distortions of the oral position and
function. Modes of action of BTX type A in oromandibular
dystonia include local chemodenervation of the motor end
plates and central intracortical inhibition, which normalizes
the distorted primary motor cortex projection. Which muscle
is injected depends on the form of dystonia, with the bilateral
masseter muscles being injected for jaw-closure dystonia, lat-
eral pterygoids with the anterior belly of the omohyoid muscle
for jaw-opening dystonia, and tongue muscles for lingual dys-
tonia. The recommended dose of BTX is 30 U per side (Tintner
and Jankovic, 2002).
4.4.4. Arthritis. This inﬂammatory joint disease manifests as
joint pain and dysfunction, with joint contractures and muscle
atrophy in advanced stages. The pain in chronic arthritis is
ampliﬁed by neuropeptide release in the periphery. BTX type
B inhibits neuropeptide release, thereby altering the nociceptor
function and reducing pain and neurogenic inﬂammation.
BTX also causes chemodenervation of the articular pain ﬁbers
(Anderson et al., 2010).
4.5. Trismus
Trismus is deﬁned as a motor disturbance of the trigeminal
nerve, especially spasm of the masticatory muscles, with difﬁ-
culty in opening the mouth. In this disorder, BTX type A acts
at the synaptic terminal of the cholinergic lower motorneuron
and causes ﬂaccid paralysis due to blockade of neuroexocytosis
at the lower motorneuron terminal presynaptically (Andrade
and Brucki, 1994). The recommended dose of BTX for trismus
is 25 U injected into each masseter muscle and 10 U into the
temporalis muscle.
4.6. Gummy smile
Gummy smile is deﬁned as the display of excessive gingival tis-
sue in the maxilla upon smiling, caused by hyperfunctional
muscles of the upper lip. Treatment with BTX type A provides
effective, minimally invasive, and temporary improvement (for
3–6 months) of gummy smile (Polo, 2005). BTX acts by cleav-
ing SNAP-25, which blocks ACh release from motorneurons
and enables repolarization of the postsynaptic terminal, result-
ing in partial chemodenervation and blockade of muscular
contraction. Muscles are injected close to the nasalis or orbic-
ularis oculi, with some muscle ﬁbers intermeshing the levator
labii superioris, levator labii superioris alaeque nasi, levator
anguli oris, and zygomaticus major and minor. The ideal dose
of BTX is about 2.5 U per side at the levator labii superiori
and zygomaticus sites, and 1.25 U per side at the orbicularis
oculi sites.4.7. Facial nerve palsy/paresis
Facial palsy refers to both incomplete loss (paresis) and com-
plete loss (paralysis) of facial nerve function. Unilateral palsy
affects the balance between the right and left sides of the face,
causing asymmetry. Injection of BTX type A into the con-
tralateral lower facial muscles weakens these muscles and
restores facial symmetry. BTX acts at the neuromuscular junc-
tion by inhibiting the release of ACh and preventing muscle
contraction. A dose of 10–80 U of BTX in saline is given intra-
muscularly, with the precise dose being tailored to each patient
and monitored by EMG. On average, the effect begins within
6 days and lasts 7–24 weeks. BTX can be re-administered,
depending on the response. A minor and self-limiting side
effect of the treatment is drooling of saliva (Sadiq et al., 2012).
4.8. Cancer therapy
Adjunctive treatment with BTX type A can be used to poten-
tiate the tumor response to chemo- or radiotherapy, by open-
ing the vascular bed. Local administration of the toxin
promotes tumor perfusion and oxygenation, and modulates
the vasoreactivity of vessels. BTX potentiates with the release
of noradrenalin, a vasomodulator that maintains sympathetic
vascular tone through activation of the vascular smooth mus-
cle adrenoceptors, in arterioles co-opted by the surrounding
tumor. Greatest effects are seen when BTX is injected 3 days
before beginning anticancer treatment (Ansiaux et al., 2006).
4.9. Carrier for oral vaccines
Recently, molecular biological techniques have been used to
generate an expression product of BTX type A. While losing
its neurotoxic effect, the expression product retains the abilities
to escape the gut, reach the general circulation, and evoke an
immune response. After the toxin is ingested, it traverses a por-
tion of the gastrointestinal system and is transcytosed from the
gut lumen to the general circulation. Circulating toxin binds to
peripheral cholinergic nerve endings, is endocytosed, and acts
as a metalloendoprotease to cleave essential polypeptides for
exocytosis. The most important mechanism for the toxin to
penetrate the gut cells is its speciﬁc binding to receptors on
the mucosal side of polarized gut cells. Bound toxin is actively
transported across cells and delivered intact and unmodiﬁed
on the serosal side of the monolayer (Simpson et al., 1999).
4.10. Oral cavity reconstruction
In spite of good postoperative care, most oral cancer patients
who are treated by tumor excision, neck dissection, and recon-
struction will encounter complications, including infections,
wound dehiscence, and ﬁstula formation. These complications
are caused by saliva stagnation due to reduced saliva clear-
ance, limited capacity to swallow, and increased saliva produc-
tion. Inﬁltration of BTX type A into the major salivary gland
4 days before surgery can help overcome these complications.
Before injection, sialometry and sialography are performed,
and gland markings are made. Then, 3–4 injections are given
to each gland, with a total dose of 80–100 U of BTX. The peak
effect is seen on days 5–8 after injection. Treatment results in a
68 M.S. Archana50–70% reduction of salivary secretion (Corradino et al.,
2012).
4.11. Dental implants, and jaw and oral surgery procedures
Failure of implant placement is mainly due to the lack of oss-
eous integration, which could be due to excessive functional
forces in patients with parafunctional habits. Treatment of
maxillofacial (e.g., zygomatic and condylar) fractures requires
multiple ﬁxation sites and hardware to overcome the forces of
masticatory musculature that prevent callus formation. Pro-
phylactic injection of 100 U of BTX type A into the masseter
muscle bilaterally 12–48 h before surgery could be beneﬁcial
in reducing these forces. In periodontal surgeries, BTX injec-
tion can reduce periodontal trauma due to excessive muscular
function (Rao et al., 2011).
4.12. Wound healing
Healing of traumatic, surgical, or other wounds (e.g., ﬁssures
and ulcers) involves multiple processes (e.g., hemostasis,
inﬂammation, tissue proliferation, and remodeling), disruption
of which can lead to a chronic wound. Increases in metabolic
activity and inﬂammation during the healing process induce
muscle contraction around the wound edges. Recently, exper-
imental treatment with BTX type A has been attempted for
wound healing, based on the ability of BTX to eliminate
dynamic tension on and around healing tissues. This chemoim-
mobilization can potentially improve healing and minimize
scarring for optimal esthetics (Lebeda et al., 2012).
Cleft lip and palate repair is generally associated with dis-
torted facial growth and retarded development of the mid-
facial region. Causes of these effects have been attributed to
a tense cheiloplasty and excessive lifting of the soft tissue,
which causes tension on the healing wound. Intraoperative
injection of BTX type A into the medial and lateral portions
of the orbicularis oris muscle has been shown to decrease mus-
cle activity, thereby decreasing tension at the surgical wound
and resulting in better healing. There has been an encouraging
trend in support of using BTX in wound-healing paradigms,
although additional studies are necessary to determine a stan-
dardized approach (Gala´rraga, 2009).Table 5 Contraindications/precautions for use of botulinum
toxin.
1. Pregnant women and nursing mothers (not yet completely
proved)
2. Use in children – could affect the nerve growth (not yet com-
pletely proved)
3. Neuromuscular disorders e.g. Myasthenia Gravis
4. Patients with impaired hemostasis
5. Cardiovascular disorders
6. Pre-existing infection at the injection site
7. Skin infections e.g. Eczeme, psoriasis
8. Individuals on aminoglycoside antibiotics, quinine, chloro-
quine, calcium channel blockers, aspirin
9. Emotionally disturbed individuals especially after the age of
65 years4.13. Hypertrophic scars
Increased deposition of collagen ﬁbers and extracellular matrix
can lead to hypertrophic scars. BTX type A inﬂuences the
ﬁbroblast cell cycle, causing decreased proliferation and
increased apoptosis. These effects, in turn, lead to decreased
expression of TGF-b1 protein. Injection with BTX type A
decreases tension at the healing site to prevent scar formation.
Studies of BTX use for hypertrophic scars have only been per-
formed in vitro, but the results are encouraging for further
in vivo studies to elucidate the mechanism and standardized
procedure for BTX use in this context (Xiao and Qu, 2012).
5. Contraindications for BTX use
Contraindications and precautions for BTX use in dentistry
are summarized in Table 5 (Muthane and Panikar, 2003).
6. Conclusions
As a group, the BTXs are the most potent of known neurotox-
ins. BTXs are clinically useful in the management of various
dental and orofacial disorders involving the muscles and
glands. BTX can be used as a helpful and minimally invasive
treatment option to improve the quality of life of patients.
As a versatile treatment option with a rapidly expanding list
of uses, this toxin offers a reversible alternative to numerous
aggressive procedures.
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